RxDoctor Payments Data

Ilva Iriarte

Psychiatry · Charleston, SCNPI 1952663445

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 75 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$481
  • Otsuka America Pharmaceutical, Inc.$183
  • AbbVie$168
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$154
  • Alkermes, Inc.$135
  • Sunovion Pharmaceuticals Inc.$132
  • plus $309 from 5 others

What the payments were for

  • Food & beverage$1,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 70th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$24,419
Medicare patients
116
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate99$283,348
Invega TrinzaPaliperidone Palmitate34$251,693
Abilify MaintenaAripiprazole61$158,323
PerserisRisperidone24$68,052
AristadaAripiprazole Lauroxil23$61,579
RexultiBrexpiprazole35$53,185
TrintellixVortioxetine Hydrobromide55$31,164
UzedyRisperidone12$29,379
Risperdal ConstaRisperidone Microspheres13$24,764
VraylarCariprazine Hcl16$23,635
Lurasidone Hcl35$17,194
Aripiprazole161$10,681
Haloperidol Decanoate130$9,766
Fluphenazine Decanoate54$6,057
Clozapine81$5,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$481$559,805146 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$183$211,50896 claims
Indivior Inc.Perseris$12$68,05224 claims
Alkermes, Inc.Aristada$135$61,57923 claims
Teva Pharmaceuticals USA, Inc.Uzedy$106$29,37912 claims
AbbVieVraylar$168$23,63516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →